# Tofacitinib In Psoriatic Arthritis Subjects With Inadequate Response to TNF Inhibitors

> **NCT01882439** · PHASE3 · COMPLETED · sponsor: **Pfizer** · enrollment: 395 (actual)

## Conditions studied

- Psoriatic Arthritis

## Interventions

- **DRUG:** Tofacitinib
- **DRUG:** Tofacitinib
- **OTHER:** Placebo
- **DRUG:** Tofacitinib
- **OTHER:** Placebo
- **DRUG:** Tofacitinib

## Key facts

- **NCT ID:** NCT01882439
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-08
- **Primary completion:** 2016-04
- **Final completion:** 2016-04
- **Target enrollment:** 395 (ACTUAL)
- **Last updated:** 2017-09-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01882439

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01882439, "Tofacitinib In Psoriatic Arthritis Subjects With Inadequate Response to TNF Inhibitors". Retrieved via AI Analytics 2026-09-28 from https://api.ai-analytics.org/clinical/NCT01882439. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*